Liver cancer working group report

Masatoshi Kudo, KwangHyub Han, Norihiro Kokudo, Ann Lii Cheng, Byung Ihn Choi, Junji Furuse, Namiki Izumi, Joong Won Park, Ronnie T. Poon, Michiie Sakamoto

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Hepatocellular carcinoma is a highly prevalent disease in many Asian countries, accounting for 75-80% of victims worldwide. The incidence of hepatocellular carcinoma varies enormously across Asia, but tends to follow the incidences of hepatitis B infection and liver cirrhosis. The incidence and etiology of hepatocellular carcinoma in Japan are different from the rest of Asia, but similar to that in Western countries because hepatitis C infection is the main etiological factor in Japan. Hepatitis B virus vaccination programs are showing great success in reducing hepatitis B virus-related hepatocellular carcinoma. Screening program improves detection of early hepatocellular carcinoma and has some positive impact on survival, but the majority of hepatocellular carcinoma patients in Asia still present with advanced hepatocellular carcinoma. Long-term outcomes following treatment of even early/intermediate or advanced disease are often unsatisfactory because of a lack of effective adjuvant and systemic therapies. Various clinical practice guidelines for hepatocellular carcinoma have been established and are in use. Clinical diagnosis of hepatocellular carcinoma by imaging diagnosis is replacing diagnosis of hepatocellular carcinoma by pathological confirmation. New imaging and treatment techniques are continuously being developed and guidelines should be updated every 3 or 4 years, incorporating new evidence. New molecularly targeted therapies hold great promise. Sorafenib is the first systemic therapy to demonstrate prolonged survival vs. the placebo in patients with advanced hepatocellular carcinoma. Various other new molecularly targeted agents are currently under investigation.

Original languageEnglish
Article numberhyq123
JournalJapanese Journal of Clinical Oncology
Volume40
Issue numberSUPPL. 1
DOIs
Publication statusPublished - 2010 Sep 1

Fingerprint

Liver Neoplasms
Hepatocellular Carcinoma
Hepatitis B virus
Incidence
Japan
Survival
Therapeutics
Hepatitis C
Infection
Hepatitis B
Practice Guidelines
Liver Cirrhosis
Vaccination
Placebos
Guidelines

All Science Journal Classification (ASJC) codes

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

Kudo, M., Han, K., Kokudo, N., Cheng, A. L., Choi, B. I., Furuse, J., ... Sakamoto, M. (2010). Liver cancer working group report. Japanese Journal of Clinical Oncology, 40(SUPPL. 1), [hyq123]. https://doi.org/10.1093/jjco/hyq123
Kudo, Masatoshi ; Han, KwangHyub ; Kokudo, Norihiro ; Cheng, Ann Lii ; Choi, Byung Ihn ; Furuse, Junji ; Izumi, Namiki ; Park, Joong Won ; Poon, Ronnie T. ; Sakamoto, Michiie. / Liver cancer working group report. In: Japanese Journal of Clinical Oncology. 2010 ; Vol. 40, No. SUPPL. 1.
@article{984607e7ff314934a17612bdc5466b99,
title = "Liver cancer working group report",
abstract = "Hepatocellular carcinoma is a highly prevalent disease in many Asian countries, accounting for 75-80{\%} of victims worldwide. The incidence of hepatocellular carcinoma varies enormously across Asia, but tends to follow the incidences of hepatitis B infection and liver cirrhosis. The incidence and etiology of hepatocellular carcinoma in Japan are different from the rest of Asia, but similar to that in Western countries because hepatitis C infection is the main etiological factor in Japan. Hepatitis B virus vaccination programs are showing great success in reducing hepatitis B virus-related hepatocellular carcinoma. Screening program improves detection of early hepatocellular carcinoma and has some positive impact on survival, but the majority of hepatocellular carcinoma patients in Asia still present with advanced hepatocellular carcinoma. Long-term outcomes following treatment of even early/intermediate or advanced disease are often unsatisfactory because of a lack of effective adjuvant and systemic therapies. Various clinical practice guidelines for hepatocellular carcinoma have been established and are in use. Clinical diagnosis of hepatocellular carcinoma by imaging diagnosis is replacing diagnosis of hepatocellular carcinoma by pathological confirmation. New imaging and treatment techniques are continuously being developed and guidelines should be updated every 3 or 4 years, incorporating new evidence. New molecularly targeted therapies hold great promise. Sorafenib is the first systemic therapy to demonstrate prolonged survival vs. the placebo in patients with advanced hepatocellular carcinoma. Various other new molecularly targeted agents are currently under investigation.",
author = "Masatoshi Kudo and KwangHyub Han and Norihiro Kokudo and Cheng, {Ann Lii} and Choi, {Byung Ihn} and Junji Furuse and Namiki Izumi and Park, {Joong Won} and Poon, {Ronnie T.} and Michiie Sakamoto",
year = "2010",
month = "9",
day = "1",
doi = "10.1093/jjco/hyq123",
language = "English",
volume = "40",
journal = "Japanese Journal of Clinical Oncology",
issn = "0368-2811",
publisher = "Oxford University Press",
number = "SUPPL. 1",

}

Kudo, M, Han, K, Kokudo, N, Cheng, AL, Choi, BI, Furuse, J, Izumi, N, Park, JW, Poon, RT & Sakamoto, M 2010, 'Liver cancer working group report', Japanese Journal of Clinical Oncology, vol. 40, no. SUPPL. 1, hyq123. https://doi.org/10.1093/jjco/hyq123

Liver cancer working group report. / Kudo, Masatoshi; Han, KwangHyub; Kokudo, Norihiro; Cheng, Ann Lii; Choi, Byung Ihn; Furuse, Junji; Izumi, Namiki; Park, Joong Won; Poon, Ronnie T.; Sakamoto, Michiie.

In: Japanese Journal of Clinical Oncology, Vol. 40, No. SUPPL. 1, hyq123, 01.09.2010.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Liver cancer working group report

AU - Kudo, Masatoshi

AU - Han, KwangHyub

AU - Kokudo, Norihiro

AU - Cheng, Ann Lii

AU - Choi, Byung Ihn

AU - Furuse, Junji

AU - Izumi, Namiki

AU - Park, Joong Won

AU - Poon, Ronnie T.

AU - Sakamoto, Michiie

PY - 2010/9/1

Y1 - 2010/9/1

N2 - Hepatocellular carcinoma is a highly prevalent disease in many Asian countries, accounting for 75-80% of victims worldwide. The incidence of hepatocellular carcinoma varies enormously across Asia, but tends to follow the incidences of hepatitis B infection and liver cirrhosis. The incidence and etiology of hepatocellular carcinoma in Japan are different from the rest of Asia, but similar to that in Western countries because hepatitis C infection is the main etiological factor in Japan. Hepatitis B virus vaccination programs are showing great success in reducing hepatitis B virus-related hepatocellular carcinoma. Screening program improves detection of early hepatocellular carcinoma and has some positive impact on survival, but the majority of hepatocellular carcinoma patients in Asia still present with advanced hepatocellular carcinoma. Long-term outcomes following treatment of even early/intermediate or advanced disease are often unsatisfactory because of a lack of effective adjuvant and systemic therapies. Various clinical practice guidelines for hepatocellular carcinoma have been established and are in use. Clinical diagnosis of hepatocellular carcinoma by imaging diagnosis is replacing diagnosis of hepatocellular carcinoma by pathological confirmation. New imaging and treatment techniques are continuously being developed and guidelines should be updated every 3 or 4 years, incorporating new evidence. New molecularly targeted therapies hold great promise. Sorafenib is the first systemic therapy to demonstrate prolonged survival vs. the placebo in patients with advanced hepatocellular carcinoma. Various other new molecularly targeted agents are currently under investigation.

AB - Hepatocellular carcinoma is a highly prevalent disease in many Asian countries, accounting for 75-80% of victims worldwide. The incidence of hepatocellular carcinoma varies enormously across Asia, but tends to follow the incidences of hepatitis B infection and liver cirrhosis. The incidence and etiology of hepatocellular carcinoma in Japan are different from the rest of Asia, but similar to that in Western countries because hepatitis C infection is the main etiological factor in Japan. Hepatitis B virus vaccination programs are showing great success in reducing hepatitis B virus-related hepatocellular carcinoma. Screening program improves detection of early hepatocellular carcinoma and has some positive impact on survival, but the majority of hepatocellular carcinoma patients in Asia still present with advanced hepatocellular carcinoma. Long-term outcomes following treatment of even early/intermediate or advanced disease are often unsatisfactory because of a lack of effective adjuvant and systemic therapies. Various clinical practice guidelines for hepatocellular carcinoma have been established and are in use. Clinical diagnosis of hepatocellular carcinoma by imaging diagnosis is replacing diagnosis of hepatocellular carcinoma by pathological confirmation. New imaging and treatment techniques are continuously being developed and guidelines should be updated every 3 or 4 years, incorporating new evidence. New molecularly targeted therapies hold great promise. Sorafenib is the first systemic therapy to demonstrate prolonged survival vs. the placebo in patients with advanced hepatocellular carcinoma. Various other new molecularly targeted agents are currently under investigation.

UR - http://www.scopus.com/inward/record.url?scp=77957268387&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957268387&partnerID=8YFLogxK

U2 - 10.1093/jjco/hyq123

DO - 10.1093/jjco/hyq123

M3 - Article

C2 - 20870915

AN - SCOPUS:77957268387

VL - 40

JO - Japanese Journal of Clinical Oncology

JF - Japanese Journal of Clinical Oncology

SN - 0368-2811

IS - SUPPL. 1

M1 - hyq123

ER -

Kudo M, Han K, Kokudo N, Cheng AL, Choi BI, Furuse J et al. Liver cancer working group report. Japanese Journal of Clinical Oncology. 2010 Sep 1;40(SUPPL. 1). hyq123. https://doi.org/10.1093/jjco/hyq123